Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s
Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s
Catherine E. Thomas,Elizabeth A. Mauer,2 Authors,L. Aronne
2016 · DOI: 10.1002/oby.21533
Obesity · 111 Citations
TLDR
The adoption of antiobesity pharmacotherapies, as compared with that of the newest antidiabetes pharmacotherapy, subtype 2 sodium‐glucose transport protein inhibitors (SGLT2s), among prescribers in the United States, is characterized.